31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration

PURPOSE: The DecisionDx-Melanoma 31-gene expression profile (31-GEP) test is validated to classify cutaneous malignant melanoma (CM) patient risk of recurrence, metastasis, or death as low (class 1A), intermediate (class 1B/2A), or high (class 2B). This study aimed to examine the effect of 31-GEP te...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Christine N., Martin, Brian J., Petkov, Valentina I., Schussler, Nicola C., Stevens, Jennifer L., Bentler, Suzanne, Cress, Rosemary D., Doherty, Jennifer A., Durbin, Eric B., Gomez, Scarlett L., Gonsalves, Lou, Hernandez, Brenda Y., Liu, Lihua, Morawski, Bożena M., Schymura, Maria J., Schwartz, Stephen M., Ward, Kevin C., Wiggins, Charles, Wu, Xiao-Cheng, Goldberg, Matthew S., Siegel, Jennifer J., Cook, Robert W., Covington, Kyle R., Kurley, Sarah J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530886/
https://www.ncbi.nlm.nih.gov/pubmed/37384864
http://dx.doi.org/10.1200/PO.23.00044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530886/
https://www.ncbi.nlm.nih.gov/pubmed/37384864
http://dx.doi.org/10.1200/PO.23.00044

Ejemplares similares